Post by Tony Crispino on May 15, 2014 7:56:12 GMT -8
Being a part of cancer research has been a fun ride this last two years. And in two weeks I get to be a part of sessions on the following abstract as a co-author
Abstract S1216
S1216 Poster Board
I now know well all the co-authors and have really enjoyed their company while we work on this clinical trial. Trial reporting shows that TAK700 is well tolerated by patients and response has been excellent. But we are still early in the research. This is a ten year trial with mortality end points. But it is gratifying to be asked to be the patient representative while the documents are drafted. My contributions were mostly to the Informed Consent Form (ICF) and several changes were made before this trial hit the streets over a year ago. Trial accrual has been strong as well. Over 1600 is the goal and over 600 is where it's at. The key questions we have right now are mostly how the data from the CHAARTED trial will stack up. And in two weeks that will be the main view of ASCO for me.
The S1216 trial will have a poster board and I'll hang around Neeraj as those sessions are going. Chicago in two weeks!
Abstract S1216
S1216 Poster Board
I now know well all the co-authors and have really enjoyed their company while we work on this clinical trial. Trial reporting shows that TAK700 is well tolerated by patients and response has been excellent. But we are still early in the research. This is a ten year trial with mortality end points. But it is gratifying to be asked to be the patient representative while the documents are drafted. My contributions were mostly to the Informed Consent Form (ICF) and several changes were made before this trial hit the streets over a year ago. Trial accrual has been strong as well. Over 1600 is the goal and over 600 is where it's at. The key questions we have right now are mostly how the data from the CHAARTED trial will stack up. And in two weeks that will be the main view of ASCO for me.
The S1216 trial will have a poster board and I'll hang around Neeraj as those sessions are going. Chicago in two weeks!
